hat
Yon apwòch se dekouvèt la ki pwòp òmtropoétin nan òmòn kò a (EPO) pa sèlman fè pwomosyon fòmasyon san, men tou, ede reparasyon blesi veso sangen. Jenetikman Enjenieri EPO ka Lè sa a, dwe itilize pou tretman. Nan Hannover Medical School, li aktyèlman ap envestige nan ki nivo erytropoetin ka itilize tou nan tretman an nan yon konjesyon serebui egi. Premye rezilta yo endike ke EPO siyifikativman diminye risk pou defisi newolojik yo.
eng
One approach is the discovery that the body's own hormone erythropoietin (EPO) not only promotes blood formation, but also helps repair injured blood vessels. Genetically engineered EPO could then be used for treatment. At the Hannover Medical School, it is currently being investigated to what extent erytrhopoetin can also be used in the treatment of an acute stroke. Initial results indicate that EPO significantly reduces the risk of neurological deficits.